Status: Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
Participants needed: 5,000
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Sep 25, 2026Locations: 771
Eligibility criteria
Participants of any sex and gender must be ≥ 18 years of age at the time of sign... [+10]
Systolic blood pressure > 180 mmHg, or diastolic BP > 110 mmHg at screening. [+4]